Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01–04) for women with stage II/III breast cancer

Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study

(2010) H. Eidtmann et al.   ANNALS OF ONCOLOGY

Zoledronic acid

(2010) Robert Coleman et al.   Expert Opinion On Drug Safety

Atrial Fibrillation and Stroke Associated With Intravenous Bisphosphonate Therapy in Older Patients With Cancer

(2010) Gregg S. Wilkinson et al.   JOURNAL OF CLINICAL ONCOLOGY

Relation of Bisphosphonate Therapies and Risk of Developing Atrial Fibrillation

(2009) T. Jared Bunch et al.   AMERICAN JOURNAL OF CARDIOLOGY

Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients

(2009) Christian Walter et al.   CANCER

Osteoporosis treatments and adverse events

(2009) Daniel H Solomon et al.   CURRENT OPINION IN RHEUMATOLOGY

Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies

(2009) T. Fehm et al.   GYNECOLOGIC ONCOLOGY

Early breast cancer

(2009) John R Benson et al.   LANCET

Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer

(2009) Michael Gnant et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pregnancy outcome following in utero exposure to bisphosphonates

(2008) Shirley Levy et al.   BONE

Risks and benefits of bisphosphonates

(2008) R E Coleman   BRITISH JOURNAL OF CANCER

Antitumor Effects of Doxorubicin Followed by Zoledronic Acid in a Mouse Model of Breast Cancer

(2008) P. D. Ottewell et al.   JNCI-Journal of the National Cancer Institute

Bisphosphonate nephrotoxicity

(2008) Mark A. Perazella et al.   KIDNEY INTERNATIONAL